Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions from September 1–3, 2025. The filings show a series of restricted share unit (RSU) grants, option exercises and open-market trades executed pursuant to a 10b5-1 plan. On September 3, 2025 the reporting person exercised a share option for 11,000 Class A Ordinary Shares at an exercise price of $17.92 and sold 11,000 shares in the market at a weighted average price of $34.84. Several RSU awards and stock options were granted or recognized on September 1–2, 2025 with various vesting schedules; one option grant has an exercise price of $33.49 and expires August 31, 2035. Following the reported transactions the reporting person beneficially owned 38,011 Class A Ordinary Shares.
Ross Moat, Chief Corporate & Commercial Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions on September 1-2, 2025. The filing shows grant and acquisition of restricted share units (RSUs) and a stock option, and reported dispositions of Class A ordinary shares at prices of $33.49 and $34.28. The derivative section shows an option for 39,364 Class A shares and RSUs representing 9,828 Class A shares, each with specified multi-year vesting schedules. Following the reported transactions, the Form 4 lists beneficial ownership figures for Class A ordinary shares in the range shown, with the last reported post-transaction direct ownership of 12,938 Class A ordinary shares. The filing includes detailed vesting terms: option vesting begins September 1, 2025, and RSUs vest over four-year schedules with 25% annual vesting.
Kiniksa Pharmaceuticals International reported Form 4 transactions for John F. Paolini, its Chief Medical Officer and a director. The filing shows multiple equity award grants and option/RSU issuances on September 1 and 2, 2025, including 9,828 RSUs, a 39,364-share option exercisable through 08/31/2035 at a $33.49 exercise price, and several additional RSU grants tied to prior grant dates. The report also discloses sales of Class A ordinary shares on September 1 (2,841 shares at $33.49) and September 2 (835 shares at $34.28). Post-transactions beneficial ownership totals are shown for each line and all holdings are reported as direct.
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported multiple equity transactions on Form 4 covering September 1-2, 2025. The filing shows grant activity including 12,275 Restricted Share Units (RSUs), a 39,363-share option with a $33.49 exercise price and several additional RSU grants and awards. It also discloses sales of Class A Ordinary Shares: 2,920 shares sold at $33.49 and 900 shares sold at $34.28. Following the reported transactions, the filing lists varying beneficial ownership totals for each line item, with direct ownership reported for all items. The form is signed by an attorney-in-fact on behalf of the reporting person.
Kiniksa Pharmaceuticals director and Chairman & CEO Sanj K. Patel reported multiple transactions on Form 4 covering September 1-2, 2025. The filing shows grants of 34,435 restricted share units (RSUs), a 137,638-share option with a $33.49 exercise price, and additional RSU grants and deliveries on those dates. The report also discloses open-market disposals: 10,983 Class A shares sold at $33.49 and 3,177 Class A shares sold at $34.28. Following the transactions, Mr. Patel beneficially owns 109,795 shares indirectly held by The Marina 2016 Irrevocable Trust and reports various direct holdings reflected in the table. Vesting schedules are specified: RSUs generally vest over four years with 25% annual vesting and the option vests 25% after one year then monthly over three years.
Kiniksa Pharmaceuticals International, plc reported a Form 144 notice for the proposed sale of 11,000 Class A ordinary shares to be executed through Charles Schwab & Co., Inc. on 09/03/2025 with an aggregate market value of $383,203.00. The shares were acquired the same day via an employee stock option exercise and the transaction will use a broker payment for a cashless exercise. The filing lists 43,472,928 shares outstanding, and shows prior sales by Michael R. Megna of 15,211 shares on 06/03/2025 (gross proceeds $437,330) and 17,000 shares on 08/04/2025 (gross proceeds $549,936). The filer certifies no undisclosed material adverse information.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to let investors know it has posted a new investor presentation on its website at investors.kiniksa.com. The company plans to use this presentation, in whole or in part and potentially with modifications, in upcoming meetings with investors, analysts and other audiences.
The investor presentation is furnished as Exhibit 99.1 to this report, with an additional cover page interactive data file listed as Exhibit 104. The filing is informational and does not announce any specific transaction or financial results.
Kiniksa Pharmaceuticals insider transactions by COO Eben Tessari show a mix of purchases and sales executed under a 10b5-1 plan. The reporting person exercised 6,500 vested options at an exercise price of $8.83 on 08/18/2025, acquiring 6,500 Class A ordinary shares. On the same date the reporting person sold 16,100 shares at a weighted-average price of $33.77 and an additional 100 shares at $34.44, reducing beneficial ownership to 40,215 shares. The Form 4 notes the trades were effected pursuant to a 10b5-1 plan executed April 29, 2024, and the option is fully vested and exercisable through 09/16/2029.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 16,200 Class A ordinary shares through Charles Schwab, with an aggregate market value of $547,070, slated for 08/18/2025 on NASDAQ. The filing documents the acquisition history for those shares, including founders' shares from 09/16/2015, two performance award lapses in 03/2022 and 03/2023, and an 08/18/2025 cashless option exercise. The filer, identified by past sales as Eben Tessari at a Lexington, MA address, sold 257,681 shares across seven transactions in May–August 2025, generating total gross proceeds of $8,111,307. The notice includes the seller's representation about lack of undisclosed material adverse information.
Insider transactions by Thomas Malley, a director of Kiniksa Pharmaceuticals International, plc (KNSA) are reported for August 12–14, 2025. The Form 4 shows multiple option exercises and open-market sales. Mr. Malley exercised stock options at strike prices ranging from $1.86 to $15.47, converting options into Class A ordinary shares. The filing reports open-market sales totaling 207,898 shares sold across three days at weighted-average sale prices in the low $30s (individual weighted averages reported at $32.4, $33.32 and $33.09). After these transactions, Mr. Malley directly beneficially owned 12,546 Class A shares and indirectly beneficially owned 71,967 shares through Mossrock Capital, LLC. The filing notes all reported options are fully vested and exercisable and includes broker execution price ranges for the sales.